Donepezil-Associated Bradycardia
Donepezil has vagotonic effects on the sinoatrial and atrioventricular nodes that can manifest as bradycardia or heart block, including syncopal episodes. [1] Clinically significant bradycardia should be managed as symptomatic bradycardia with evaluation for reversible causes and removal of potential offending medications. [2]
Immediate Stabilization and Initial Evaluation
Hemodynamic instability (hypotension, altered mental status, ischemic chest pain, acute heart failure, shock) requires emergent management per bradycardia/conduction-delay pathways. [2] A 12-lead ECG should be obtained promptly to characterize rhythm and conduction pattern. [2] Atropine is a reasonable acute pharmacologic option for symptomatic bradycardia attributable to atrioventricular nodal level block. [2] Potential causative medications should be identified and removed when clinically plausible, including cholinesterase inhibitors. [2]
Medication Review and Donepezil Modification
Donepezil should be withheld when clinically important bradycardia occurs, with reassessment for alternative causes and medication-related contribution. [3] Cholinesterase inhibitors should be used with caution in patients with bradycardia or cardiac conduction disorders because of increased risk of syncope and falls. [4] Co-prescribed rate-slowing drugs (including beta-blockers and non-dihydropyridine calcium channel blockers) should be reviewed because they increase the likelihood of clinically significant bradyarrhythmia. [2]
Acute Symptom-Driven Rate Support
For second-degree or third-degree atrioventricular block with symptoms or hemodynamic compromise, atropine is reasonable to improve atrioventricular conduction and ventricular rate. [2] For atrioventricular block with symptoms or hemodynamic compromise and low likelihood of coronary ischemia, beta-adrenergic agonists (such as isoproterenol, dopamine, dobutamine, or epinephrine) may be considered to improve atrioventricular conduction and ventricular rate. [2] For atrioventricular block with symptoms or hemodynamic compromise refractory to medical therapy, temporary pacing is reasonable to increase heart rate and improve symptoms. [2]
Device Therapy and Reversibility Assessment
Permanent pacing decisions should be based on persistent symptomatic bradyarrhythmia after evaluation for reversible causes. [2] In selected patients requiring ongoing clinically necessary antiarrhythmic or beta-blocker therapy, permanent pacing may be pursued without further observation for drug washout or reversibility. [2] Medication-related bradycardia from donepezil should be treated as a reversible-cause scenario during acute management and follow-up reassessment. [1]
Targeted Monitoring During Workup and Follow-Up
Continuous cardiac monitoring should be used until the rhythm cause is clarified and symptoms resolve or stabilize. [2] If bradycardia resolves after donepezil withholding, reassessment should focus on whether the bradyarrhythmia recurs with rechallenge versus switching to an alternative therapy. [3] Patients with prior syncope and bradycardia on donepezil should be monitored closely after any medication changes or dose adjustments. [1]
Common Pitfalls to Avoid
Bradycardia should not be attributed to donepezil without ECG-based confirmation of the bradyarrhythmia mechanism because management differs by conduction pattern and level of block. [2] Atropine should be used judiciously in atrioventricular block with wide QRS complexes suggesting His-Purkinje disease because atropine may be less likely to improve conduction and may worsen hemodynamic compromise in some settings. [2] Failure to review concomitant rate-slowing medications increases the risk of persistent or recurrent symptomatic bradyarrhythmia. [2]
Goals of Therapy
The goals are restoration of adequate heart rate and perfusion while reversible causes are removed and definitive management is determined based on persistent versus resolved bradyarrhythmia. [2] For medication-related bradycardia, symptom resolution after donepezil withholding supports medication contribution and guides longer-term continuation versus discontinuation strategy. [1]